Monoclonal Antibody News and Research

RSS

Monoclonal antibodies (MAbs) are produced from a single B cell clone and can bind to a single type of antigen binding site. MAbs are homogenous antibodies that cannot form lattices with monomeric proteins as they can bind to only a single epitope on the antigen. Developed in the 1970s, MAbs can be produced against any given substance. Thus they can be used to detect and purify any substance of interest. This has made MAbs a powerful tool of molecular biology, biochemistry, and medicine.

Dotmatics Biology Solution for Antibody Discovery streamlines data collection and workflows to accelerate antibody research and therapies

...

From Dotmatics 5 May 2022

Human nose organoids reveal the first events of SARS-CoV-2 and RSV infection

Preclinical models that recapitulate aspects of human airway disease are essential for the advancement of novel therapeutics and vaccines.

16 Feb 2022

Single-cell sequencing technique helps to examine early SARS-CoV-2 infection

In the early days of SARS-CoV-2 infection in the lungs, what happens at the single-cell level?

14 Feb 2022

A folic acid-like drug changes a DNA process within brain tumors

A folic acid-like drug, L-methylfolate, when administered alongside the standard therapy for patients with recurrent glioblastoma, changed aDNA process within their brain tumors, according to results from a phase 1 clinical trial.

From Vanderbilt University 6 Jan 2022

Duke engineers develop a rapid test to identify antibody effectiveness against COVID-19 variants

Biomedical engineers at Duke University have devised a test to quickly and easily assess how well a person's neutralizing antibodies fight infection from multiple variants of COVID-19 such as Delta and the newly discovered Omicron variant.

6 Dec 2021

Study finds amphipathic peptide that safely opens endosomal membrane

The cell plasma membrane and the derived endosomal membranes are both greasy barriers that prevent the inflow of water-soluble macromolecules like nucleic acids and proteins into cells.

2 Dec 2021

Sphere Fluidics closes a $40 million funding round led by Sofinnova Partners and Redmile Group

Sphere Fluidics announced today that it has closed a $40 million (circa £30 million) investment round.

From Sphere Fluidics 28 Oct 2021

Experts develop antibodies that effectively remove senescent cells

The reason why some people age worse than others and develop diseases linked to the aging mechanism is largely unknown.

22 Oct 2021

Study identifies highly potent monoclonal antibody against all SARS-CoV-2 variants

Researchers identified a greatly potent monoclonal antibody that aims at the spike protein of SARS-CoV-2.

19 Oct 2021

Novel Assay Platform for 3D Microfluidic Cancer Research

AMSBIO have supplied custom Chimeric antigen receptor (CAR)-T products to the University of Strathclyde (UoS) in Glasgow, UK, and ScreenIn3D Ltd, allowing them to perform novel immune-oncology assays in 3D microfluidic cancer models.

From AMS Biotechnology 1 Oct 2021

New map provides a reference to predict which antibodies are effective against SARS-CoV-2

Scientists at La Jolla Institute for Immunology have published a detailed map of where human antibodies bind to SARS-CoV-2, a map that was generated by a global collaboration comparing nearly all leading clinical candidates.

24 Sep 2021

Researchers provide novel treatment target for common skin condition

Recent research indicates that a familiar inflammatory skin condition might arise due to inadequately regulated sex hormones.

23 Sep 2021

New drug delivery strategy could make it easier for patients to take their medications

In recent years, scientists have developed monoclonal antibodies -; proteins that mimic the body's own immune defenses -; that can combat a variety of diseases, including some cancers and autoimmune disorders such as Crohn's disease.

31 Aug 2021

Newly designed higher affinity monoclonal antibody for cancer treatment

Recently, Prof. XIE Can from the High Magnetic Field Laboratory of the Hefei Institutes of Physical Science (HFIPS), in a collaboration with Prof. YAN Xiyun's lab from the Institute of Biophysics, reported the structural basis of mAb AA98's inhibition on CD146-mediated endothelial cells (EC) activation and designed higher affinity monoclonal antibody HA98 for cancer treatment.

10 May 2021

Key discovery could prevent treatment failure in people with severe hemophilia A

Recently, researchers achieved a crucial discovery that could mitigate and eliminate immune responses causing treatment failure in people with hemophilia A.

20 Apr 2021

Immunity of COVID-19 patients may rely on antibodies from previous coronavirus infections

The results of a study led by Northern Arizona University and the Translational Genomics Research Institute (TGen), an affiliate of City of Hope, suggest the immune systems of people infected with COVID-19 may rely on antibodies created during infections from earlier coronaviruses to help fight the disease.

22 Jan 2021

COVID-19 virus triggers antibody response from prior coronavirus infections

According to the results of a study, the immune systems of COVID-19 patients may depend on antibodies that were produced during infections from previous coronaviruses to help combat the disease.

20 Jan 2021

Proteogenomic study may lead to more effective treatments for head and neck squamous cell carcinoma

Proteogenomic studies may provide a better understanding of how to match cancer patients with an effective treatment for their specific cancer.

8 Jan 2021

Triple drug combination keeps people with metastatic colon cancer disease free for longer time

Researchers from SWOG Cancer Research Network, a cancer clinical trials group funded by the National Cancer Institute (NCI), part of the National Institutes of Health, have shown that a triple drug combination - of irinotecan, cetuximab, and vemurafenib - is a more powerful tumor fighter and keeps people with metastatic colon cancer disease free for a significantly longer period of time compared with patients treated with irinotecan and cetuximab.

24 Dec 2020

New analysis technique could pave way for major breakthroughs in immunotherapy

In a new study, researchers at Uppsala University have been able to show differences in how Rituximab, a monoclonal antibody drug, interacts with the blood of healthy individuals compared to patients with chronic lymphatic leukaemia.

14 Dec 2020